Vanacof AC Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed or recommended Vanacof AC — a combination of chlophedianol hydrochloride and pyrilamine maleate — are increasingly encountering difficulty filling it at retail pharmacies. While there is no active FDA-declared shortage, Vanacof AC's limited distribution network creates real access barriers for patients who depend on a decongestant-free cough-and-antihistamine product. This guide provides a clinical overview for healthcare providers.

Clinical Overview: Vanacof AC's Active Ingredients

Vanacof AC (manufactured by GM Pharmaceuticals, Inc.) is an oral liquid providing per 30 mL dose:

Chlophedianol HCl 12.5 mg: A centrally-acting non-narcotic antitussive. Mechanism of action is not fully elucidated but is thought to involve CNS suppression of the cough reflex. Not a controlled substance, not an opioid, with lower abuse potential than codeine-based antitussives.

Pyrilamine Maleate 25 mg: A first-generation H1 antihistamine. Provides sedation as a side effect, blocks histamine-mediated rhinorrhea, sneezing, and pruritus. Shorter half-life than second-generation antihistamines; crosses the blood-brain barrier, producing CNS effects.

The product is formulated without a decongestant (no pseudoephedrine or phenylephrine), making it suitable for patients with cardiovascular disease, hypertension, benign prostatic hyperplasia, or hyperthyroidism who require cough and allergy symptom management.

Why Patients Are Having Trouble Filling Vanacof AC

The availability problem stems primarily from distribution, not manufacturing. GM Pharmaceuticals distributes through a regional pharmacy network, and Vanacof AC is not carried in the standard formulary of major chain pharmacies (CVS, Walgreens, Rite Aid, Walmart Pharmacy). When patients present to their usual chain pharmacy, they frequently find that the product is neither in stock nor orderable through that pharmacy's wholesaler.

Key contributing factors:

Small manufacturer with limited national distribution reach

Concentrated demand from a niche patient population (decongestant-intolerant)

Seasonal demand spikes during fall/winter respiratory illness season

Formulary and shelf space competition from higher-volume national brands

Therapeutic Alternatives for Clinical Consideration

When Vanacof AC cannot be filled, the following alternatives provide comparable pharmacologic coverage:

Ninjacof (chlophedianol/pyrilamine, OTC): Identical active ingredients and drug class. Best direct substitution with no clinical adjustment needed.

Vanacof CP (chlophedianol/pyrilamine, OTC): Same manufacturer, same ingredients (12.5 mg/25 mg per 15 mL). Different dose volume from Vanacof AC (30 mL vs. 15 mL) but same total dose per administration.

Chlorpheniramine/Dextromethorphan (OTC): Widely stocked. Substitutes a different antihistamine (chlorpheniramine, first-gen) and a different antitussive (dextromethorphan). Effective and widely available; no decongestant in standard Coricidin HBP formulation.

Promethazine/Dextromethorphan (Rx): For patients needing stronger antihistamine coverage or sedation at night. No decongestant; available as generic liquid. Monitor for over-sedation, particularly in elderly patients.

Benzonatate (Rx): If cough suppression is the primary goal and antihistamine coverage is not required, benzonatate (100–200 mg TID PRN) is a locally-acting antitussive alternative without antihistamine effects.

Patient Populations That Most Need Decongestant-Free Options

The clinical rationale for specifically seeking a decongestant-free product like Vanacof AC typically applies to patients with:

Hypertension or cardiovascular disease (pseudoephedrine may increase blood pressure and heart rate)

Benign prostatic hyperplasia (decongestants can worsen urinary retention)

Hyperthyroidism (adrenergic stimulation from decongestants may exacerbate symptoms)

Narrow-angle glaucoma (contraindication for most decongestants)

Patients on MAO inhibitors (combination with pseudoephedrine can cause hypertensive crisis)

Prescribing Tips to Reduce Patient Frustration

When recommending or prescribing Vanacof AC, note the equivalent alternatives (Ninjacof, Vanacof CP) on the prescription or in visit notes so the patient can request them if needed.

Consider prescribing a slightly larger quantity during initial fills to reduce how often patients need to locate the product.

Direct patients to independent pharmacies rather than chain pharmacies, which are more likely to stock specialty products like Vanacof AC.

Recommend medfinder to patients who struggle with pharmacy access — it calls pharmacies on the patient's behalf to identify where their medication is available.

A Tool for Your Patients: medfinder

medfinder is a service designed to help patients locate hard-to-find medications at nearby pharmacies without making endless phone calls. Patients provide their medication, dosage, and location, and medfinder's team calls pharmacies on their behalf and delivers results by text. This is particularly useful for specialty products like Vanacof AC with limited distribution. Learn more about how to refer your patients at medfinder.com/providers.

See also: How to Help Your Patients Find Vanacof AC in Stock: A Provider's Guide.